Screening status in relation to biological and chronological characteristics of breast cancers: A cross sectional survey

Journal of Medical Screening

Volumn 4, Issue 3, 1997, Pages 152-157

  Alexander, Freda E ^a   Anderson, Thomas J ^a   Hubbard, Alexandra L ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Biology; Breast cancer; Chronology; Prognostic factors

Indexed keywords

ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PREVENTION; CANCER SCREENING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PROGNOSIS; RECEPTOR DENSITY;

EID: 0031395460     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1177/096914139700400308     Document Type: Article

References (34)

1. Roberts MM, Alexander FE, Anderson TJ, et al. The Edinburgh randomised trial of screening for breast cancer: description of method. Br J Cancer 1984;50:1-6.
2. Duffy S, Tabar L, Fagerberg G, et al. Breast screening, prognostic factors and survival - results from the Swedish two county study. Br J Cancer 1991;64:1133-8.
3. Mittra I. Axillary lymph node metastasis in breast cancer: prognostic indicator or lead-time bias? Eur J Cancer 1993; 29A:300-2.
4. Anonymous. Prognostic factors in breast cancer: biology or chronology? [editorial]. Lancet 1992;340:517-18.
5. Mittra I, MacRae KD. A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology? Eur J Cancer 1991;27:1574-83.
6. Tubiana M, Koscielny S. Natural history of human breast cancer: recent data and clinical implications. Breast Cancer Res Treat 1991;18:125-40.
7. Tubiana-Hulin M, Hacene K, Martin PM, et al. Prognostic factor clustering in breast cancer : biology or chronology. Eur J Cancer 1994;31:283-4.
8. Hubbard AL, Doris CP, Thompson AM, Chetty U, Anderson TJ. Critical determination of the frequency of c-erb-B-2 amplification in breast cancer. Br J Cancer 1993; 70:434-9.
9. Hawkins RA, Black R, Steele RJC, Dixon JMJ, Forest APM. Oestrogen receptor concentration in primary breast cancer and auxiliary node metastases. Breast Canc Res Treat 1981; 1:245-51.
10. Page DL, Anderson TJ. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987.
11. Sloane JP, Anderson TJ, Davies J, et al. Pathology reporting in breast cancer screening. 2nd ed. Sheffield: NHSBSP Publications, 1995.
12. Gullick WJ, Bergor MS, Bennett PLP, Rothbard JB, Waterfield MD. Expression of the c-erb B-2 protein in normal and transformed cells. Int J Cancer 1987;40:246-54.
13. Stenberger LA. Immunocytochemistry. 3rd ed. New York: Wiley, 1986:103-9.
14. Cox DR. Analysis of binary data. London: Chapman and Hall, 1970. (Monographs on applied probability and statistics.)
15. Mehta CR, Patel NR, Gray R. On computing an exact interval for the common odds ratio in several 2 x 2 contingency tables. Journal of the American Statistical Association, 1985;80:969-73.
16. Statistics and Epidemiology Research Corporation. EGRET: state-of-the art epidemiological computing. Houston, USA: Conceptional Software Inc, 1991.
17. Carter CL, Allen C, Henson DE. Relation of tumour size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
18. Alexander FE, Anderson TJ, Brown HK, et al. The Edinburgh randomised trial of breast cancer screening: results after 10 years follow-up. Br J Cancer 1994;70:542-8.
19. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Gronfoft O. Breast cancer treatment and natural history: new insights from results of screening. Lancet 1992;339: 412-14.
20. Anderson TJ, Lamb J, Donnan P, Alexander FE, Huggins A. Comparative pathology of breast cancer in a randomised trial of screening. Br J Cancer 1991;64:108-13.
21. Hakama HM, Holli K, Isola J, et al. Aggressiveness of screen detected breast cancers. Lancet 1995;345:221-4.
22. Roberts MM, Hawkins RA, Alexander FE, Anderson TJ, Steele RJC. Oestrogen receptor activity in breast cancer detected at a prevalence screening examination. Breast Canc Res Treat 1987;10:267-72.
23. Singleton TP, Strickler JG. Clincal and pathological significance of the c-erb B2 (HER-2/neu) oncogene. Pathol Annu 1992;27:165-90.
24. Day NE, Williams DDR, Khaw KT. Breast cancer screening programs: the development of a monitoring and evaluating system. Br J Cancer 1989;59:954-8.
25. Morrison AS. Intermediate determinants of mortality in the evaluation of screening. Int J Epidemiol 1991;20:642-50.
26. Cowan WK, Angus B, Henry J, Corbett P, Reid WA, Horne CHN. Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening. Br J Cancer 1991;64:780-4.
27. Alexander FE, Anderson TJ. Population breast cancer screening. Lancet 1995;345:854.
28. AndersonTJ, Alexander FE, Kirkpatrick AE. Maximize compliance as well as radiological sensitivity. BMJ 1995;310:1002-3.
29. Tabar L, Fagerberg CJG, Gad A, et al. What is the optimal interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer 1987;55: 547-51.
30. Woodman CBJ, Threfall AG, Boggis CRM, Prior P. Is the three year breast screening interval too long? Occurrence of interval cancer in NHS breast screening programme's north western region? BMJ 1995;310:224-6.
31. Tabár L. Breast screening in Britain [editorial]. J Med Screen 1995;2:179.
32. Moss SM, Ellman R, Colman D, Chamberlain J. Survival of patients with breast cancer diagnosed in the United Kingdom trial of early detection of breast cancer. J Med Screen 1994;1:193-8.
33. Moss SM, Michel M, Patnick J, Johns L, Blanks R, Chamberlain J. Results from the NHS breast screening programme 1990-1993. J Med Screen 1995;2:186-90.
34. Day NE, Duffy SW, Chen HH. Survival and interim end points in breast cancer [letter] J Med Screen 1995;2:57.